(CLDX) Celldex Therapeutics - Ratings and Ratios
Antibody, Vaccine, Cancer
CLDX EPS (Earnings per Share)
CLDX Revenue
Description: CLDX Celldex Therapeutics
Celldex Therapeutics Inc (NASDAQ:CLDX) is a biotechnology company listed on the NASDAQ stock exchange, operating in the biotechnology sub-industry. The companys stock is characterized by high volatility, as indicated by its beta of 1.223, suggesting that its stock price is more volatile than the overall market.
The stocks recent price movement shows a current price of $20.01, below its short-term and long-term moving averages, indicating a potential downtrend. The Average True Range (ATR) of 1.16 represents a 5.77% daily price range, highlighting the stocks volatility. With an average trading volume of 865,236 shares, the stock has sufficient liquidity.
From a fundamental perspective, Celldex Therapeutics has a market capitalization of $1.37 billion, indicating a mid-cap company. The absence of a Price-to-Earnings (P/E) ratio and a negative Return on Equity (RoE) of -27.62% suggests that the company is currently unprofitable. Key economic drivers for the companys stock performance include progress in its clinical trials, regulatory approvals, and the overall demand for its products or services.
To evaluate the companys potential, key performance indicators (KPIs) such as revenue growth, cash burn rate, and the advancement of its pipeline products are crucial. Investors should also consider the competitive landscape, managements track record, and the overall outlook for the biotechnology sector. A thorough analysis of these factors can help investors make informed decisions about investing in Celldex Therapeutics.
CLDX Stock Overview
| Market Cap in USD | 1,513m |
| Sub-Industry | Biotechnology |
| IPO / Inception | 2008-03-10 |
CLDX Stock Ratings
| Growth Rating | -36.1% |
| Fundamental | 24.5% |
| Dividend Rating | - |
| Return 12m vs S&P 500 | -50.0% |
| Analyst Rating | 4.57 of 5 |
CLDX Dividends
Currently no dividends paidCLDX Growth Ratios
| Growth Correlation 3m | 56.5% |
| Growth Correlation 12m | -61.2% |
| Growth Correlation 5y | -7.3% |
| CAGR 5y | -5.59% |
| CAGR/Max DD 3y | -0.08 |
| CAGR/Mean DD 3y | -0.17 |
| Sharpe Ratio 12m | -2.11 |
| Alpha | 0.06 |
| Beta | 0.738 |
| Volatility | 50.64% |
| Current Volume | 1247.2k |
| Average Volume 20d | 1385.5k |
| Stop Loss | 23 (-6%) |
| Signal | -0.29 |
Piotroski VR‑10 (Strict, 0-10) 1.0
| Net Income (-199.6m TTM) > 0 and > 6% of Revenue (6% = 347.5k TTM) |
| FCFTA -0.23 (>2.0%) and ΔFCFTA -10.16pp (YES ≥ +1.0pp, WARN ≥ +0.5pp) |
| NWC/Revenue 10.6k% (prev 9447 %; Δ 1180 pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp) |
| CFO/TA -0.27 (>3.0%) and CFO -186.2m > Net Income -199.6m (YES >=105%, WARN >=100%) |
| NO Net Debt/EBITDA fails (EBITDA <= 0) |
| Current Ratio 19.67 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active) |
| Outstanding Shares last Quarter (66.4m) change vs 12m ago 0.56% (target <= -2.0% for YES) |
| Gross Margin 72.28% (prev 62.68%; Δ 9.60pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0) |
| Asset Turnover 0.75% (prev 0.98%; Δ -0.23pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0) |
| error: Interest Coverage Ratio cannot be calculated (needs EBITDA TTM and Interest Expense TTM) |
Altman Z'' -51.23
| (A) 0.89 = (Total Current Assets 648.4m - Total Current Liabilities 33.0m) / Total Assets 692.4m |
| (B) -2.41 = Retained Earnings (Balance) -1.67b / Total Assets 692.4m |
| warn (B) unusual magnitude: -2.41 — check mapping/units |
| (C) -0.31 = EBIT TTM -234.7m / Avg Total Assets 769.0m |
| (D) -44.92 = Book Value of Equity -1.66b / Total Liabilities 37.0m |
| Total Rating: -51.23 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D) |
ValueRay F-Score (Strict, 0-100) 24.45
| 1. Piotroski 1.0pt = -4.0 |
| 2. FCF Yield -17.98% = -5.0 |
| 3. FCF Margin data missing |
| 4. Debt/Equity 0.01 = 2.50 |
| 5. Debt/Ebitda -0.02 = -2.50 |
| 6. ROIC - WACC (= -32.48)% = -12.50 |
| 7. RoE -27.62% = -2.50 |
| 8. Rev. Trend 13.73% = 1.03 |
| 9. EPS Trend -51.59% = -2.58 |
What is the price of CLDX shares?
Over the past week, the price has changed by -2.00%, over one month by -0.08%, over three months by +21.93% and over the past year by -40.69%.
Is Celldex Therapeutics a good stock to buy?
Based on momentum, paid dividends and discounted-cash-flow analyses, the fair value of CLDX is around 20.73 USD . This means that CLDX is currently overvalued and has a potential downside of -15.25%.
Is CLDX a buy, sell or hold?
- Strong Buy: 10
- Buy: 2
- Hold: 2
- Sell: 0
- Strong Sell: 0
What are the forecasts/targets for the CLDX price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 55.6 | 127.4% |
| Analysts Target Price | 55.6 | 127.4% |
| ValueRay Target Price | 23.2 | -5.3% |
Last update: 2025-09-05 04:37
CLDX Fundamental Data Overview
CCE Cash And Equivalents = 630.3m USD (Cash And Short Term Investments, last quarter)
P/S = 261.2677
P/B = 2.3922
Beta = 1.193
Revenue TTM = 5.79m USD
EBIT TTM = -234.7m USD
EBITDA TTM = -231.4m USD
Long Term Debt = 4.04m USD (from nonCurrentLiabilitiesTotal, last quarter)
Short Term Debt = 1.54m USD (from shortTermDebt, last quarter)
Debt = 5.57m USD (Calculated: Short Term 1.54m + Long Term 4.04m)
Net Debt = -20.0m USD (from netDebt column, last quarter)
Enterprise Value = 888.0m USD (1.51b + Debt 5.57m - CCE 630.3m)
Interest Coverage Ratio = unknown (Ebit TTM -234.7m / Interest Expense TTM 0.0)
FCF Yield = -17.98% (FCF TTM -159.7m / Enterprise Value 888.0m)
FCF Margin = -2758 % (FCF TTM -159.7m / Revenue TTM 5.79m)
Net Margin = -3447 % (Net Income TTM -199.6m / Revenue TTM 5.79m)
Gross Margin = 72.28% ((Revenue TTM 5.79m - Cost of Revenue TTM 1.60m) / Revenue TTM)
Tobins Q-Ratio = -0.53 (set to none) (Enterprise Value 888.0m / Book Value Of Equity -1.66b)
Interest Expense / Debt = 55.79% (Interest Expense 3.11m / Debt 5.57m)
Taxrate = 21.0% (US default)
NOPAT = -234.7m (EBIT -234.7m, no tax applied on loss)
Current Ratio = 19.67 (Total Current Assets 648.4m / Total Current Liabilities 33.0m)
Debt / Equity = 0.01 (Debt 5.57m / last Quarter total Stockholder Equity 655.4m)
Debt / EBITDA = -0.02 (Net Debt -20.0m / EBITDA -231.4m)
Debt / FCF = -0.03 (Debt 5.57m / FCF TTM -159.7m)
Total Stockholder Equity = 722.8m (last 4 quarters mean)
RoA = -28.83% (Net Income -199.6m, Total Assets 692.4m )
RoE = -27.62% (Net Income TTM -199.6m / Total Stockholder Equity 722.8m)
RoCE = -32.30% (Ebit -234.7m / (Equity 722.8m + L.T.Debt 4.04m))
RoIC = -32.48% (NOPAT -234.7m / Invested Capital 722.8m)
WACC = unknown (E(1.51b)/V(1.52b) * Re(8.73%)) + (D(5.57m)/V(1.52b) * Rd(none%) * (1-Tc(0.21)))
Shares Correlation 3-Years: 100.00 | Cagr: 3.21%
Discount Rate = 8.73% (= CAPM, Blume Beta Adj.)
Fair Price DCF = unknown (Cash Flow -159.7m)
EPS Correlation: -51.59 | EPS CAGR: -45.62% | SUE: 0.11 | # QB: 0
Revenue Correlation: 13.73 | Revenue CAGR: 23.67% | SUE: -0.36 | # QB: 0
Additional Sources for CLDX Stock
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle